New mouthwash: an efficacious intervention for oral ulceration associated with Behçet's disease

• Published in: British journal of oral & maxillofacial surgery Vol. 58; no. 8; pp. 1034 - 1039
• Main Authors: Senusi, Amal, Kang, Angray, Buchanan, John A.G, Adesanya, Adebowale, Aloraini, Ghfren, Stanford, Miles, Fortune, Farida
• Format: Journal Article
• Language: English
• Published: Scotland Elsevier Ltd 01.10.2020
• Subjects: BD mouthwash (BD MW); Behcet Syndrome - complications; Behcet Syndrome - drug therapy; Behçet's disease (BD); Cross-Sectional Studies; Dentistry; Female; Humans; Male; Mouthwashes - therapeutic use; Oral Health Quality of Life (OHQoL); Oral Ulcer - drug therapy; Oral Ulcer - etiology; Oral ulcer severity score (OUSS); Quality of Life; Retrospective Studies; Behçet's disease (BD); Oral ulcer severity score (OUSS); Oral Health Quality of Life (OHQoL); BD mouthwash (BD MW)
• ISSN: 0266-4356; 1532-1940
• DOI: 10.1016/j.bjoms.2020.07.027

Topical interventions to treat oral ulcers in Behçet's disease (BD) are crucial to control disease activity and improve patients’ quality of life. Our aim was to evaluate the effectiveness of a new BD mouthwash (BD MW) for oral ulceration. A retrospective cross-sectional study was carried out on 261 BD patients (141 women, mean (SD) age 39.9 (11.8) years, and 120 men, mean (SD) age 41.141(3.7) years). All were assessed using the oral ulcer severity score (OUSS), oral health quality of life (OHQoL), and the Behçet's disease current activity form (BDCAF). Patients were divided into three groups: one group used the BD MW, one group used a betamethasone mouthwash, and the other used no therapeutic mouthwash. Patients were assessed at three and six months. The OUSS in those using the BD MW was nine times lower than it was in those using betamethasone mouthwash (p=0.001), and 12 times lower than it was in the no mouthwash group (p=0.001). Compared with the baseline data, use of the BD MW during the first three months significantly reduced the OUSS, the BDCAF score, and intraoral scarring, and also improved OHQoL (p=0.001, 0.019, 0.012, and 0.001, respectively). Ongoing use of the BD MW after six months significantly improved the OUSS, OHQoL, and intraoral scars, and kept oral and systemic disease activity under control. A total of 20/31 patients reported high levels of satisfaction with its use, and a patients’ satisfaction score showed a preference for it. This study confirms the efficacy of the BD MW in patients with recurrent oral ulceration (ROU). It is more efficacious than betamethasone mouthwash used alone.